Human research on CBD for depression is thin. The NCCIH fact sheet on cannabis and cannabinoids says that “Research on cannabis or cannabinoids for other conditions is in its early stages.” The strongest study in the evidence is a 2025 randomized trial in 180 highly stressed university students at risk of depression. Both a CBD oil group and a placebo oil group improved more than a no-treatment group, but the CBD oil did not beat the placebo oil on any outcome. None of the studies here establishes that CBD relieves depression, and the only trial enrolled 180 highly stressed university students described as at risk of depression; the abstract does not say whether any participant had a diagnosed depressive disorder.
What human clinical evidence exists for CBD and depression?
Two human studies and one case report are in the evidence. Only one is a randomized trial.
The 2025 randomized trial in students
The 2025 trial published in the Journal of Cannabis Research randomized 180 students to 30 days of a daily oil: a 10% full spectrum CBD oil, a placebo oil, or no treatment. Its outcomes were perceived stress and psychological distress, measured before the intervention, after it, and at a 4-week follow-up. After 30 days the groups differed significantly in decreases of stress, depressive symptoms and somatization, but not in anxiety, sleep quality or wellbeing. The CBD group and the placebo group both benefited more than the no-treatment group. No significant difference in any outcome was shown between the CBD oil and the placebo oil. The authors wrote that they “could not find a differential efficacy of CBD treatment” and that the results “suggest a substantial placebo response.” The trial was pre-registered on 22/12/2022 as DRKS00030971.
The 2022 exploratory survey
A 2022 exploratory cohort in Frontiers in Psychiatry surveyed 90 people aged 16 to 69 who used CBD to self-treat depression symptoms. The survey was distributed online and included the validated Hospital Depression and Anxiety Scale. The abstract reports who these people were and whom they told: only 19% consulted a doctor or pharmacist about taking CBD, and among psychiatric patients only 49% told their psychiatrist. The abstract describes a single survey of users and does not report a comparison group or how their scores changed. It describes who uses CBD for depression, not whether it helps them. The authors call for “education and research on the efficacy and safety of CBD use for mental disorders.”
Why animal studies cannot support symptom claims
The 2024 study in Brain Sciences is the animal study in the evidence. Female Long Evans Hooded rats received doxorubicin, a chemotherapy drug, and then oral CBD. Researchers measured anxiety- and depression-like behaviors and the expression of inflammatory markers. The study reports that CBD was “significantly protective” against these behaviors in rats. Symptom claims should not be carried over from it to people with depression for three reasons:
- The subjects were rats given a chemotherapy drug, not people with depression.
- The outcomes were behavioral tests and gene expression in brain tissue, not a person”s mood or symptom scores.
- The authors frame the work as “insights into future studies on possible mechanisms,” not as proof of symptom relief.
What the evidence cannot tell you
- Whether CBD helps people with a diagnosed depressive disorder. The only trial enrolled students at risk of depression.
- Whether any benefit lasts. The trial’s follow-up measure came 4 weeks after 30 days of intervention.
- Which dose or product would be used. This page gives no dose, and the studies here do not establish one for depression.
- Whether CBD works better than placebo. The 2025 trial found no difference from placebo oil on any outcome.
For why one small study cannot settle a broad question, see Understanding Emerging Research: Preliminary Findings.
| Study | Population | Formulation | Comparator | Outcome | Duration | Harms | Certainty |
|---|---|---|---|---|---|---|---|
| 2025 randomized trial | 180 highly stressed university students at risk of depression | 10% full spectrum CBD oil, daily | Placebo oil and no-treatment control | Greater reduction in stress, depressive symptoms and somatization than no treatment; no CBD vs placebo difference on any outcome | 30 days, measured again at 4-week follow-up | Not described in the abstract | Randomized and pre-registered; no CBD-specific effect; substantial placebo response |
| 2022 exploratory cohort | 90 people aged 16 to 69 self-treating depression symptoms | Not stated in the abstract | None reported in the abstract | Hospital Depression and Anxiety Scale collected; score changes not reported in the abstract | Not stated in the abstract | Not described in the abstract | Exploratory survey; cannot show benefit |
| 2024 rat study | Female Long Evans Hooded rats given doxorubicin | Oral CBD | Vehicle-treated rats | Less anxiety- and depression-like behavior in behavioral tests; changes in inflammatory marker expression in hippocampus and prefrontal cortex | Four weeks of doxorubicin, then CBD for the same period | Not described in the abstract | Animal study; not evidence about human depression |
| 2020 case report | One pediatric patient | CBD-labeled oil | None | Respiratory depression; intubation; pediatric intensive care for 48 hours | Discharged after 72 hours | Respiratory depression; unresponsiveness | Single case; not a depression study |
Safety: what the 2020 case report describes
A 2020 case report in the Journal of the American Pharmacists Association describes a child who was found unresponsive after a dose of CBD oil. His respiratory drive continued to deteriorate, he was intubated, and he was moved out of the pediatric intensive care unit after 48 hours and discharged after 72 hours. A urine test showed a THC metabolite at 123 ng/mL. Samples from the same batch, tested by the manufacturer and by the U.S. Food and Drug Administration, contained only trace amounts of THC. The authors write that “purity, potency, labeling, and delivery devices remain inconsistent.” This is one child’s case, not a depression study, but it shows why label accuracy matters. The abstracts of the 2022 survey and the 2025 trial do not describe side effects.
Legal status as of October 16, 2026
The 2020 case report says that sales of CBD products not approved by the Food and Drug Administration “remain illegal at the federal level.” That is the authors’ 2020 statement, and it does not tell you the federal status as of October 16, 2026. Check the current status with the Food and Drug Administration. This is information, not legal advice.
What do medical guidelines say about CBD for depression?
No medical guideline recommending or rejecting CBD for depression is discussed on this page, so no guideline position is reported here. The positions on record are the studies’ own conclusions, and they are not equally strong. The randomized trial is the strongest design in the evidence and found no CBD-specific effect. The rat study is the weakest guide to people, because it tested rats. The 2022 survey describes users and calls for more research.
Your next step: a qualified mental health assessment
If you are dealing with low mood or depression, a qualified mental health professional can assess what is happening and help you plan treatment. Tell them about any CBD use. The 2022 survey found that most respondents did not consult a doctor or pharmacist about CBD, so this is the conversation to have before anything else. The NIDA cannabis research topic page reports that “Some research has also shown an increased risk of depression in people who use cannabis during adolescence.” For questions about telehealth visits, see Cannabis Telehealth: Symptoms, Safety and Cost Guide. For the psychosis question, which this page does not answer, see Cannabis and Psychosis Risk: What the Studies Show.
Before your appointment
- Bring the product label and tell your clinician what you have been taking and how you have been taking it.
- Ask what the evidence says about your own situation. The 2025 trial enrolled students at risk of depression and does not describe your case.
- Ask about any product testing that is available. The 2020 case report notes that purity, potency and labeling remain inconsistent.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.